Here's What Key Metrics Tell Us About MacroGenics (MGNX) Q3 Earnings

MacroGenics (MGNX) reported $110.71 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 964.5%. EPS of $0.90 for the same period compares to -$0.52 a year ago.The reported revenue represents a surprise of +14.09% over the Zacks Consensus Estimate of $97.04 million. With the consensus EPS estimate being $0.17, the EPS surprise was +429.41%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how MacroGenics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenue- Product sales, net: $4.16 million versus the four-analyst average estimate of $6.05 million. The reported number represents a year-over-year change of -11.4%. Revenue- Collaborative and other agreements: $101.41 million versus $72.94 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +11358.5% change. Revenue- Government agreements: $0.57 million versus $0.45 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +64.1% change. View all Key Company Metrics for MacroGenics here>>>Shares of MacroGenics have returned +3.1% over the past month versus the Zacks S&P 500 composite's -0.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Research Chief Names "Single Best Pick to Double"From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report MacroGenics, Inc. (MGNX): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks